Euroopan unioni - suomi - EMA (European Medicines Agency)

otsuka novel products gmbh - delamanid - tuberkuloosi, monilääkeresistenssi - mykobakteerilÄÄkkeet - deltyba is indicated for use as part of an appropriate combination regimen for pulmonary multi-drug resistant tuberculosis (mdr-tb) in adults, adolescents, children and infants with a body weight of at least 10 kg when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability (see sections 4. 2, 4. 4 ja 5. on otettava huomioon viralliset ohjeet antibioottien tarkoituksenmukaisesta käytöstä.

Euroopan unioni - suomi - EMA (European Medicines Agency)

astrazeneca ab - dapagliflosiinipropaanidiolimonohydraatti - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - diabeetilla käytettävät lääkkeet - type 2 diabetes mellitusedistride is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance. lisäksi muiden lääkkeiden hoitoon tyypin 2 diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 ja 5. heart failureedistride is indicated in adults for the treatment of symptomatic chronic heart failure. chronic kidney diseaseedistride is indicated in adults for the treatment of chronic kidney disease.

Euroopan unioni - suomi - EMA (European Medicines Agency)

novartis europharm limited - sacubitril, valsartaanin - sydämen vajaatoiminta - angiotensiini ii-reseptorin salpaajat, muut yhdistelmät, agentit reniini-angiotensiini-järjestelmä - paediatric heart failureentresto is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic heart failure with left ventricular systolic dysfunction. adult heart failureentresto is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction.

Euroopan unioni - suomi - EMA (European Medicines Agency)

viiv healthcare bv - lamivudiini - hiv-infektiot - antiviraalit systeemiseen käyttöön - epiviri on merkitty osana antiretroviraalista yhdistelmähoitoa ihmisen immuunikatoviruksen (hiv) infektoituneiden aikuisten ja lasten hoitoon.

Euroopan unioni - suomi - EMA (European Medicines Agency)

astrazeneca ab - a/darwin/9/2021 (h3n2) - like strain (a/norway/16606/2021, medi 355293) / a/victoria/2570/2019 (h1n1)pdm09 - like strain (a/victoria/1/2020, medi 340505) / b/austria/1359417/2021 - like strain (b/austria/1359417/2021, medi 355292) / b/phuket/3073/2013 - like strain (b/phuket/3073/2013, medi 306444) - influenssa, ihminen - influenssa influenssa, elävä heikennetty - prophylaxis of influenza in children and adolescents from 24 months to less than 18 years of age. fluenz tetran käytön olisi perustuttava virallisiin suosituksiin.

Euroopan unioni - suomi - EMA (European Medicines Agency)

astrazeneca ab - dapagliflosiinipropaanidiolimonohydraatti - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - diabeetilla käytettävät lääkkeet - type 2 diabetes mellitusforxiga is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance. lisäksi muiden lääkkeiden hoitoon tyypin 2 diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 ja 5. heart failureforxiga is indicated in adults for the treatment of symptomatic chronic heart failure. chronic kidney diseaseforxiga is indicated in adults for the treatment of chronic kidney disease.

Euroopan unioni - suomi - EMA (European Medicines Agency)

csl behring gmbh - ihmisen normaali immunoglobuliini (scig) - immunologiset puutosyhtymät - immunoseerumit ja immunoglobuliinit, - replacement therapy in adults, children and adolescents (0-18 years) in:- primary immunodeficiency syndromes with impaired antibody production (see section 4. - secondary immunodeficiencies (sid) in patients who suffer from severe or recurrent infections, ineffective antimicrobial treatment and either proven specific antibody failure (psaf)* or serum igg level of.

Euroopan unioni - suomi - EMA (European Medicines Agency)

takeda pharmaceuticals international ag ireland branch - guanfasiinihydrokloridia - attention deficit disorder with hyperactivity - antiadrenergic agents, centrally acting, antihypertensives, - intuniv is indicated for the treatment of attention deficit hyperactivity disorder (adhd) in children and adolescents 6 17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective. intuniv on käytettävä osana kokonaisvaltaista adhd-hoito-ohjelman, tyypillisesti myös psykologisia, kasvatuksellisia ja sosiaalisia toimenpiteitä.

Euroopan unioni - suomi - EMA (European Medicines Agency)

teva b.v. - lipegfilgrastim - neutropenia - immunostimulantit, , kasvutekijät - lonquex is indicated in adults and in children 2 years of age and older for reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).

Euroopan unioni - suomi - EMA (European Medicines Agency)

novartis europharm limited - sacubitril, valsartaanin - sydämen vajaatoiminta - reniini-angiotensiinijärjestelmään vaikuttavat aineet - paediatric heart failureneparvis is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic heart failure with left ventricular systolic dysfunction (see section 5. adult heart failureneparvis is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction (see section 5.